您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报 (医学版) ›› 2020, Vol. 58 ›› Issue (10): 120-126.doi: 10.6040/j.issn.1671-7554.0.2020.0741

• 临床医学 • 上一篇    下一篇

新型冠状病毒IgM-IgG抗体检测试剂盒的制备及对15例患者临床应用初试

李焕杰1,2,欧兰香3,陈虹4,陈健2,耿军2,高志鹏5,王岩3,丁兴龙3,陈振3,朱之炜3,刘伦琴4,汪运山1,2   

  1. 1. 山东大学齐鲁医学院临床医学院, 山东 济南 250012;2. 山东大学附属济南市中心医院医学实验诊断中心, 山东 济南 250013;3. 山东莱博生物科技有限公司, 山东 济南 250101;4. 山东大学附属济南市传染病医院, 山东 济南 250021;5. 潍坊市人民医院重症医学科, 山东 潍坊 261000
  • 发布日期:2020-10-08
  • 通讯作者: 汪运山. E-mail:sdjnwys@163.com
  • 基金资助:
    中国博士后科学基金新冠疫情防控专项(2020T130070ZX);济南市新冠肺炎防控应急科技攻关计划(202001005-3,202001001-1,202001006-3)

Development and clinical value evaluation of IgM-IgG antibody detection kit for SARS-CoV-2 infection in 15 cases

LI Huanjie1,2, OU Lanxiang3, CHEN Hong4, CHEN Jian2, GENG Jun2, GAO Zhipeng5, WANG Yan3, DING Xinglong3, CHEN Zhen3, ZHU Zhiwei3, LIU Lunqin4, Wang Yunshan1,2   

  1. 1. School of Medicine, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China;
    2. Medical Research &
    Laboratory Diagnostic Center, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250013, Shandong, China;
    3. Shandong Laibo Biotechnology Co. Ltd, Jinan 250101, Shandong, China;
    4. Jinan Infectious Disease Hospital, Shandong University, Jinan 250021, Shandong, China;
    5. Department of Intensive Care Medicine, Weifang Peoples Hospital, Weifang 261000, Shandong, China
  • Published:2020-10-08

PDF (PC)

307

摘要： 目的 开发一种快速检测SARS-CoV-2病毒的IgM-IgG抗体的胶体金免疫层析检测试剂盒,并优化研发及应用策略,分析IgM-IgG抗体联合检测在新冠病毒检测中的临床应用价值。 方法 表达纯化SARS-CoV-2病毒S蛋白的RBD和NTD结构域,通过胶体金制备工艺包被抗原及多克隆抗体,制备IgM-IgG抗体检测试剂盒;收集15例阳性患者的血清进行抗体检测分析,计算试剂盒检测的阳性率,分析SARS-CoV-2抗体IgM-IgG对病毒响应的过程。 结果 在15例核酸RT-PCR检测阳性的患者血清样本中,IgM-IgG联合抗体检测的阳性率为73.33%,其中IgM阳性占总标本数的53.33%,IgG阳性占总标本数的60.00%;5例境外人员中有3例为抗体阳性;对患者的流行病学分析发现,病毒感染1周以上的患者共7例,抗体检测全部为阳性;抗体检测试剂盒的灵敏度73.33%,特异性95.00%。 结论 IgM-IgG联合抗体检测法具有快速、方便、易操作等特点,可以作为核酸检测的辅助手段对疑似患者(尤其是境外人员及无症状患者)进行初筛;且IgM-IgG的检测结果可以作为推测患者病毒感染过程的依据;快速检测IgM-IgG抗体将为COVID-19疾病的诊断和治疗提供帮助。

关键词: 新型冠状病毒, IgM-IgG抗体检测, 新型冠状病毒肺炎, 核酸检测, 胶体金法

Abstract: Objective To develop a colloidal gold kit for rapid detection of IgM-IgG antibodies of SARS-CoV-2, optimize the development and application strategy, and investigate the diagnostic value of SARS-CoV-2 IgM-IgG antibodies by detecting serum of clinically confirmed patients. Methods The RBD and NTD domains of S protein from SARS-CoV-2 virus were expressed and purified to prepare IgM-IgG antibody colloidal gold detection kit by coating antigen and polyclonal antibody with preparation technique of colloidal gold, then the clinical efficacy was validated. The blood samples collected from 15 PCR confirmed COVID-19 patients were detected and the positive rate was calculated to analyze the response progress of SARS-CoV-2 antibody IgM-IgG on virus. Results The overall positive rate of IgM-IgG antibody assay test was 73.33%, which was higher that single IgM(positive rate: 53.33%)or IgG(positive rate: 60.00%)test. Three cases were positive out of five aliens. The epidemiology analyses showed that 7 positive cases had infected with SARS-CoV-2 virus for more than one week. The sensitivity of the antibody detection kit was 73.33% and the specificity was 95.00%. Conclusion The IgM-IgG combined test method is rapid, convenient and easy to operate, and can be used to carry on the primary screening for the suspected patients, especially the aliens and asymptomatic patients. On the other hand, the IgM-IgG detection result can be used as the basis to infer the virus-infected progress. The rapid dection results of IgM-IgG antibody may be helpful for the diagnosis and treatment on COVID-19.

Key words: SARS-CoV-2, IgM-IgG antibody detection, COVID-19, Nucleic acid test, Colloidal gold method

中图分类号: 

  • R446.5
[1] World Health Organization. Coronavirus disease(COVID-2019)situation reports[EB/OL].(2020-05-06)[2020-05-06]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/.
[2] Centers for Disease Control and Prevention. Cases, Data, & Surveillance, Locations with confirmed COVID-19 cases, global map [EB/OL].(2020-05-06)[2020-05-06]. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html.
[3] Li H, Wang Y, Ji M, et al. Transmission routes analysis of SARS-CoV-2: a systematic review and case report [J]. Front Cell Dev Biol, 2020, 8: 618. doi: 10.3389/fcell.2020.00618.
[4] 国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第七版)[EB/OL].(2020-03-04)[2020-05-06]. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
[5] 谭明凯, 区静怡, 黄颖, 等. 新型冠状病毒3种抗体试剂盒的性能评估及临床应用初探 [J]. 中华微生物学和免疫学杂志, 2020, 40(4): 250-255. TAN Mingkai, QU Jingyi, HUANG Ying, et al. Performance evaluation and clinical application of three antibody test kits for novel coronavirus [J]. Chinese Journal of Microbiology and Immunology, 2020, 40(4): 250-255.
[6] Paraskevis D, Kostaki EG, Magiorkinis G, et al. Full-genome evolutionary analysis of the novel corona virus(2019-nCoV)rejects the hypothesis of emergence as a result of a recent recombination event [J]. Infect Genet Evol, 2020, 79: 104212. doi:10.1016/j.meegid.2020.104212.
[7] Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China [J]. Nature, 2020, 579(7798): 265-269.
[8] Wan YS, Shang J, Graham R, et al. Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS [J]. J Virol, 2020, 94(7): e00127-20. doi:10.1128/JVI.00127-20.
[9] Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin [J]. Nature, 2020, 579(7798): 270-273.
[10] Chu DKW, Pan Y, Cheng SMS, et al. Molecular diagnosis of a novel coronavirus(2019-nCoV)causing an outbreak of pneumonia[J]. Clin Chem, 2020, 66(4): 549-555.
[11] Liu Y, Liu Y, Diao B, et al. Diagnostic indexes of a rapid IgG/IgM combined antibody test for SARS-CoV-2 [J]. medRxiv, 2020. doi: https://doi.org/10.1101/2020.03.26.20044883.
[12] Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis [J]. J Med Virol, 2020, 92(10): 1518-1524.
[13] Xie J, Ding C, Li J, et al. Characteristics of patients with coronavirus disease(COVID-19)confirmed using an IgM-IgG antibody test [J]. J Med Virol, 2020, 92(10): 2004-2010.
[14] Adams ER, Andersson MI, Anand R, et al. Antibody testing for COVID-19: a report from the national COVID scientific advisory panel[J]. 2020, 5:139, doi: 10.12688/wellcomeopenres.15927.1.
[15] Liu W, Liu L, Kou G, et al. Evaluation of nucleocapsid and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies against SARS-CoV-2 [J]. J Clin Microbiol, 2020, 58(6): e00461-20. doi:10.1128/JCM.00461-20.
[16] Racine R, Winslow GM. IgM in microbial infections: taken for granted? [J]. Immunol Lett, 2009, 125(2): 79-85.
[17] Lee HK, Lee BH, Seok SH, et al. Production of specific antibodies against SARS-coronavirus nucleocapsid protein without cross reactivity with human coronaviruses 229E and OC43 [J]. J Vet Sci, 2010, 11(2): 165-167.
[18] Guo H, Hu BJ, Yang XL, et al. Evolutionary arms race between virus and host drives genetic diversity in bat SARS related coronavirus spike genes [J]. J Virol, 2020: JVI.00902-20. doi: 10.1128/JVI.00902-20.
[19] Chi X, Yan R, Zhang J, et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability [J]. bioRxiv, 2020. doi:https://doi.org/10.1101/2020.05.08.083964.
[20] Jiang S, Hillyer C, Du L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses [J]. TrendsI Immunol, 2020, 41(5): 355-359.
[21] Qu J, Wu C, Li X, et al. Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)[J]. Clin Infect Dis, 2020: ciaa489. doi: 10.1093/cid/ciaa489.
[22] Lee YL, Liao CH, Liu PY, et al. Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients [J]. J Infect, 2020, 81(2): e55-e58. doi: 10.1016/j.jinf.2020.04.019.
[23] 汪运山, 申红, 姜莉华, 等. SARS-CoV抗体实验诊断中的假阳性原因分析 [J]. 山东大学学报(医学版), 2003, 41(4): 92-94. WANG Yunshan, SHEN Hong, JIANG Lihua, et al. Analysis of false-positive associated with antibody tests for SARS-CoV [J]. Journal of Shandong University(Health Sciences), 2003, 41(4): 92-94.
[24] 李晖, 李咏茵, 张志高, 等. 2019新型冠状病毒抗体胶体金检测方法的建立与临床性能评价 [J]. 中华传染病杂志, 2020, 38(3): 139-144. LI Hui, LI Yongyin, ZHANG Zhigao, et al. Establishment and clinical performance evaluation of 2019 novel coronavirus antibody colloidal gold detection method [J] , Chinese Journal of Infectious Diseases, 2020, 38(3): 139-144.
[1] 王彬,布学慧,孔祥亘,张照华,吴谙诏,肖迪,蒋雪梅. 成人37例与儿童10例新型冠状病毒肺炎的临床特点比较[J]. 山东大学学报 (医学版), 2020, 58(10): 112-116.
[2] 王玲,曹海霞,张玲,张文娜,潘艳萍,史颖,张伟,崔峰. 淄博市一起新型冠状病毒肺炎家族聚集性疫情调查分析[J]. 山东大学学报 (医学版), 2020, 58(10): 100-104.
[3] 白尧,陈志军,宋姝璇,贺真,陈保忠,邵中军,刘昆. 西安市一起新型冠状病毒肺炎家族聚集性疫情调查分析[J]. 山东大学学报 (医学版), 2020, 58(10): 95-99.
[4] 张辉, 宋姝璇, 刘继锋, 贺真, 邵中军, 刘昆. 西安市新型冠状病毒肺炎疫情分析[J]. 山东大学学报 (医学版), 2020, 58(10): 89-94.
[5] 刘利利,贾艳,齐畅,朱雨辰,李春雨,佘凯丽,刘廷轩,李秀君. 基于时空统计方法分析温州市2020年1~3月新型冠状病毒肺炎的聚集性分布[J]. 山东大学学报 (医学版), 2020, 58(10): 82-88.
[6] 刘廷轩,齐畅,佘凯丽,贾艳,朱雨辰,李春雨,刘利利,王旭,章志华,李秀君. 河北省新型冠状病毒肺炎流行特征与时空聚集性分析[J]. 山东大学学报 (医学版), 2020, 58(10): 74-81.
[7] 贾艳,李春雨,刘利利,佘凯丽,刘廷轩,朱雨辰,齐畅,张丹丹,王旭,陈恩富,李秀君. 浙江省新型冠状病毒肺炎的流行特征与空间分析[J]. 山东大学学报 (医学版), 2020, 58(10): 66-73.
[8] 齐畅,朱雨辰,李春雨,刘利利,张丹丹,王旭,佘凯丽,陈鸣,康殿民,李秀君. 基于地理加权广义线性模型探索山东省新型冠状病毒肺炎的影响因素[J]. 山东大学学报 (医学版), 2020, 58(10): 53-59.
[9] 佘凯丽,张丹丹,齐畅,刘廷轩,贾艳,朱雨辰,李春雨,刘利利,王旭,苏虹,李秀君. 安徽省新型冠状病毒肺炎流行病学特征及其潜伏期估计[J]. 山东大学学报 (医学版), 2020, 58(10): 44-52.
[10] 李春雨,朱雨辰,齐畅,刘利利,张丹丹,王旭,徐学利,李秀君. 河南省信阳市新型冠状病毒肺炎的流行动态[J]. 山东大学学报 (医学版), 2020, 58(10): 38-43.
[11] 朱雨辰,李春雨,齐畅,王莹,刘利利,张丹丹,王旭,康殿民,李秀君. 基于泊松过程的山东省新型冠状病毒肺炎的再生数估计及流行动态分析[J]. 山东大学学报 (医学版), 2020, 58(10): 32-37.
[12] 金新叶,卢珍珍,丁中兴,陈峰,彭志行. 武汉交通管制和集中隔离对新型冠状病毒肺炎疫情影响的动力学模型研究[J]. 山东大学学报 (医学版), 2020, 58(10): 25-31.
[13] 徐丽君,刘文辉,刘远,李美霞,罗雷,欧春泉. SEIQCR传染病模型的构建及在广州市新型冠状病毒肺炎公共卫生防控效果评估中的应用[J]. 山东大学学报 (医学版), 2020, 58(10): 20-24.
[14] 李秀君,李新楼,刘昆,赵晓波,马盟,孙博. 地理信息系统在新型冠状病毒肺炎疫情防控中的应用进展述评[J]. 山东大学学报 (医学版), 2020, 58(10): 13-19.
[15] 孔祥亘,布学慧,王彬,蒋雪梅. 新型冠状病毒病患者病毒核酸反复阳性超60天2例报告[J]. 山东大学学报 (医学版), 2020, 58(10): 117-119.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发